BREAKING
NVIDIA (NVDA) eyes China AI chip re-entry as export licensing shifts to case-by-case review 3 days ago Qualcomm (QCOM) authorizes $20B stock repurchase program, raises quarterly dividend to $0.92 3 days ago UP Fintech Holding Limited Reports Strong 2025 Results 3 days ago FedEx (FDX) Q3 Earnings Crush Estimates: EPS of $5.25 Beats by 27% on $24B Revenue 3 days ago Cato Corporation 2025 Financial Results Summary 3 days ago GROY Posts Breakeven Q4 Earnings, Beating Estimates by 100% as Revenue Grows 34.2% YoY to $4.5M 3 days ago York Space Systems (YSS) Posts -$0.24 EPS vs. -$0.18 Est., Revenue Soars to $105.3M 3 days ago Scholastic (SCHL) Q3 Loss Narrows to $0.15/Share vs $0.36 Estimate, Revenue Misses at $329.1M 3 days ago Curis (CRIS) EPS Soars 210.8% to $1.23, But Revenue Plunges 67.1% to $1.1M 3 days ago Eton Pharmaceuticals (ETON) Q4 Revenue Surges 82.9% YoY to $21.3M, EPS Climbs 266.7% 3 days ago NVIDIA (NVDA) eyes China AI chip re-entry as export licensing shifts to case-by-case review 3 days ago Qualcomm (QCOM) authorizes $20B stock repurchase program, raises quarterly dividend to $0.92 3 days ago UP Fintech Holding Limited Reports Strong 2025 Results 3 days ago FedEx (FDX) Q3 Earnings Crush Estimates: EPS of $5.25 Beats by 27% on $24B Revenue 3 days ago Cato Corporation 2025 Financial Results Summary 3 days ago GROY Posts Breakeven Q4 Earnings, Beating Estimates by 100% as Revenue Grows 34.2% YoY to $4.5M 3 days ago York Space Systems (YSS) Posts -$0.24 EPS vs. -$0.18 Est., Revenue Soars to $105.3M 3 days ago Scholastic (SCHL) Q3 Loss Narrows to $0.15/Share vs $0.36 Estimate, Revenue Misses at $329.1M 3 days ago Curis (CRIS) EPS Soars 210.8% to $1.23, But Revenue Plunges 67.1% to $1.1M 3 days ago Eton Pharmaceuticals (ETON) Q4 Revenue Surges 82.9% YoY to $21.3M, EPS Climbs 266.7% 3 days ago
ADVERTISEMENT
Market News

MannKind posts narrower-than-expected Q1 loss

MannKind Corporation (NASDAQ: MNKD) reported a narrower loss in the first quarter of 2019 helped by higher total revenues. The bottom line was narrower than the analysts’ expectations while the top line exceeded consensus estimates. Net loss was $14.88 million or $0.08 per share, narrower than the previous year quarter’s loss of $30.39 million or […]

May 7, 2019 2 min read
Market News

MannKind Corporation (NASDAQ: MNKD) reported a narrower loss in the first quarter of 2019 helped by higher total revenues. The bottom line was narrower than the analysts’ expectations while the top line exceeded consensus estimates. Net loss was $14.88 million or $0.08 per share, narrower than the previous year quarter’s loss of $30.39 million or […]

MannKind Corporation (NASDAQ: MNKD) reported a narrower loss in the first quarter of 2019 helped by higher total revenues. The bottom line was narrower than the analysts’ expectations while the top line exceeded consensus estimates.

Net loss was $14.88 million or $0.08 per share, narrower than the previous year quarter’s loss of $30.39 million or $0.25 per share.

Total revenues soared by 404% to $17.45 million. The top line reflected Afrezza net revenues of $5.1 million and collaboration and services revenue of $12.4 million.

Image Courtesy: MannKind / Facebook post

Afrezza net revenue increased by 49% primarily driven by higher product demand and a more favorable mix of cartridges and price. Collaborations and services revenue increased to $12.37 million from $63,000 a year ago, primarily due to the United Therapeutics licensing and research agreements.

For the first quarter, research and development expenses dropped by 37% year-over-year to $1.7 million. The decrease was primarily attributable to $0.4 million decreases in both lower clinical trial spending and lower personnel costs.

Also read: Regeneron Q1 2019 earnings results

Selling, general and administrative expenses increased by 25% to $25.7 million. This was primarily due to spending on direct-to-consumer television advertising offset by a decrease in personnel costs, a decrease in stock-based compensation expense, and a decrease in professional fees.

Cash, cash equivalents, restricted cash, and short-term investments at March 31, 2019, fell to $59.8 million from $71.7 million at December 31, 2018. The decrease was primarily due to net cash used in operating activities of $11.6 million in the first quarter of 2019, which included the receipt of a $12.5 million milestone payment from United Therapeutics.

Shares of MannKind ended Monday’s regular session up 1.31% at $1.55 on the Nasdaq. Following the earnings release, the stock inched up over 3% in the premarket session.

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

ADVERTISEMENT